15 completed, 1 active not recruiting. 7 Phase 1, 5 Phase 2, 4 Phase 3.
By phase and status
Follow CIN-107: new trials by email Literature Review of CIN-107 trials Research Report on CIN-107
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|
Parent Study: A Study to Assess Efficacy and Safety of Baxdrostat in Participants With Primary Aldosteronism Sub-study: A Follow-up Substudy After Completion of the BaxPA Main Study.
Baxdrostat, Placebo - Primary Hyperaldosteronism | Phase 3 | Active not recruiting | AstraZeneca | 212 | 2025-08-07 | 2026-10-16 |
A Study to Evaluate Cortisol Reserve in Response to Adrenocorticotropic Hormone (ACTH) Stimulation Test Following Baxdrostat Treatment Compared to Placebo in Participants With Uncontrolled Hypertension
Baxdrostat, Placebo - Uncontrolled Hypertension | Phase 2 | Completed | AstraZeneca | 48 | 2024-06-10 | 2025-12-17 |
A Study to Investigate the Pharmacokinetics of Baxdrostat When Given Alone and in Combination With Itraconazole in Healthy Participants
Baxdrostat, Itraconazole - Healthy Participants | Phase 1 | Completed | AstraZeneca | 14 | 2024-04-16 | 2024-07-03 |
A Study to Investigate the Efficacy and Safety of Baxdrostat in Participants With Uncontrolled Hypertension on Two or More Medications Including Participants With Resistant Hypertension
Baxdrostat, Placebo - Uncontrolled Hypertension, Resistant Hypertension | Phase 3 | Completed | AstraZeneca | 326 | 2024-04-08 | 2026-04-21 |
A Study to Investigate the Effect of Baxdrostat on Ambulatory Blood Pressure in Participants With Resistant Hypertension
Baxdrostat, Placebo - Resistant Hypertension | Phase 3 | Completed | AstraZeneca | 218 | 2024-03-01 | 2026-08-06 |
A Study to Investigate the Efficacy and Safety of Baxdrostat in Participants With Uncontrolled Hypertension on Two or More Medications Including Participants With Resistant Hypertension
Baxdrostat, Placebo - Uncontrolled Hypertension, Resistant Hypertension | Phase 3 | Completed | AstraZeneca | 796 | 2023-11-22 | 2026-07-30 |
Baxdrostat Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study in a Japanese Population
baxdrostat - Hypertension | Phase 1 | Completed | AstraZeneca | 41 | 2022-07-05 | 2023-08-14 |
A Study to Evaluate CIN-107 for the Treatment of Patients With Uncontrolled Hypertension and Chronic Kidney Disease
CIN-107, Placebo - Uncontrolled Hypertension, Chronic Kidney Diseases | Phase 2 | Completed | AstraZeneca | 195 | 2022-04-29 | 2025-05-20 |
Open-Label Extension Study of Patients Previously Enrolled in Study CIN-107-124
CIN-107 - Hypertension | Phase 2 | Completed | AstraZeneca | 175 | 2022-04-06 | 2024-12-16 |
A Study of CIN-107 in Patients With Uncontrolled Hypertension
CIN-107, Placebo - Uncontrolled Hypertension | Phase 2 | Completed | CinCor Pharma, Inc. | 249 | 2021-12-07 | 2023-08-01 |
Phase 1 Study to Determine the Metabolism and Clearance of Baxdrostat
baxdrostat - Hypertension | Phase 1 | Completed | AstraZeneca | 8 | 2021-11-18 | 2023-08-15 |
Phase 1 PK Study to Evaluate the PK of CIN-107 in Subjects With Hepatic Impairment
baxdrostat - Hypertension | Phase 1 | Completed | AstraZeneca | 20 | 2021-08-10 | 2023-08-14 |
Study to Evaluate the Pharmacokinetics of CIN-107 in Subjects With Varying Degrees of Renal Function
CIN-107 - Hypertension | Phase 1 | Completed | AstraZeneca | 33 | 2021-01-12 | 2023-08-14 |
Study to Evaluate the Effect of CIN-107 on the Pharmacokinetics of the MATE Substrate, Metformin, in Healthy Subjects
Metformin, CIN-107 - Hypertension | Phase 1 | Completed | AstraZeneca | 27 | 2020-10-28 | 2023-08-14 |
A Study of CIN-107 in Adults With Treatment-Resistant Hypertension (rHTN)
CIN-107, Placebo - Resistant Hypertension | Phase 2 | Completed | CinCor Pharma, Inc. | 275 | 2020-10-12 | 2023-07-24 |
Study With CIN-107 Following Multiple Oral Ascending Doses in Healthy Subjects
CIN-107, Matching Placebo - Hypertension | Phase 1 | Completed | AstraZeneca | 56 | 2019-12-19 | 2023-08-14 |
Conditions studied
Hypertension (10) · Hyperaldosteronism (1) · Renal Insufficiency, Chronic (1)
Sponsors
AstraZeneca (14) · CinCor Pharma, Inc. (2)
Countries
United States (15) · Australia (4) · Argentina (3) · Canada (3) · Germany (3) · India (3) · Japan (3) · Spain (3) · Taiwan (3) · Turkey (Türkiye) (3) · United Kingdom (3) · Vietnam (3) · Belgium (2) · Bulgaria (2) · China (2)
Top investigators
Eric Lawitz, MD (1) · Kimberly Cruz, MD (1) · Leela Leela Vrishabhendra, MD, MD (1) · Leela Vrishabhendra, MD (1) · Nicholas Siebers, MD Siebers, MD (1) · Peter J Winkle, MD (1) · Thomas Marbury, MD (1) · William B Smith,, MD (1) · Zeid Kayali, MD (1)
Results publications
PMID 40850955, PMID 40913594, PMID 37490693, PMID 39138914, PMID 40888730, PMID 41794437
NIH funding
2023 (2)